Target Validation Information
Target ID T80896
Target Name Estrogen receptor beta
Target Type
Successful
Drug Potency against Target 7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one Drug Info IC50 = 1530 nM [528152]
2,3-diphenyl-1H-indole Drug Info IC50 = 171 nM [527797]
HEXESTROL Drug Info IC50 = 2 nM
ONAPRISTONE Drug Info Ki < 20 nM [534119]
3-chloro-4-(4-hydroxyphenyl)salicylaldoxime Drug Info Ki = 12 nM [529314]
4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol Drug Info IC50 = 11.9 nM [527797]
4-(3-phenyl-1H-indol-2-yl)phenol Drug Info IC50 = 355 nM [527797]
EFFUSOL Drug Info IC50 = 12 nM [527966]
DIHYDRORALOXIFENE Drug Info IC50 = 0.52 nM [525493]
Pipendoxifene Drug Info IC50 = 40 nM [526057]
TUPICHINOL C Drug Info IC50 = 14700 nM [530935]
2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol Drug Info IC50 = 60 nM [527681]
6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol Drug Info IC50 = 3.2 nM [527966]
8-n-pentylnaringenin Drug Info IC50 = 97 nM [528557]
8-n-propylnaringenin Drug Info IC50 = 29 nM [528557]
Afimoxifene Drug Info IC50 = 20 nM [529739]
8-(3-methylbutyl)naringenin Drug Info IC50 = 59 nM [528557]
6-(3-Hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 30 nM [527584]
6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol Drug Info IC50 = 17 nM [527584]
6-(2-Hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 2000 nM [527584]
8-(2,2-dimethylpropyl)naringenin Drug Info IC50 = 141 nM [528557]
8-n-heptylnaringenin Drug Info IC50 = 69 nM [528557]
2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol Drug Info IC50 = 1190 nM [527681]
8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 2.3 nM [527584]
DIADZEIN Drug Info IC50 = 1200 nM [526493]
1-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 2.52 nM [527584]
1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 13 nM [527584]
2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol Drug Info IC50 = 82 nM [527232]
5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol Drug Info IC50 = 30 nM [527681]
2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol Drug Info IC50 = 1.1 nM [526532]
4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol Drug Info IC50 = 240 nM [526589]
4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol Drug Info IC50 = 45 nM [527966]
3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol Drug Info IC50 = 963 nM [527232]
3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one Drug Info IC50 = 49 nM [527966]
4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol Drug Info IC50 = 4.6 nM [527681]
4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol Drug Info IC50 = 4.3 nM [527681]
3-hydroxy-4,7-dimethyl-6H-benzo[c]chromen-6-one Drug Info IC50 = 93 nM [527966]
6-(3-Hydroxy-phenyl)-naphthalen-1-ol Drug Info IC50 = 205 nM [527584]
2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol Drug Info IC50 = 11 nM [527232]
6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 2.3 nM [527584]
3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol Drug Info IC50 = 181 nM [527232]
7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol Drug Info IC50 = 2 nM [527198]
1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 9 nM [527584]
2-(4-Hydroxy-phenyl)-benzooxazol-6-ol Drug Info IC50 = 50 nM [527232]
6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 11 nM [527584]
6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol Drug Info IC50 = 10 nM [527584]
7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol Drug Info IC50 = 1.6 nM [527198]
4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol Drug Info IC50 = 105 nM [527232]
2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol Drug Info IC50 = 235 nM [527232]
7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 13 nM [527232]
2-(4-Hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 49 nM [527232]
2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 239 nM [527232]
6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 16 nM [527232]
2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol Drug Info IC50 = 5 nM [527232]
7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 79 nM [527232]
2-Naphthalen-1-yl-benzooxazol-6-ol Drug Info IC50 = 1050 nM [527232]
4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol Drug Info IC50 = 8 nM [527966]
3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol Drug Info IC50 = 54 nM [527232]
2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol Drug Info IC50 = 15 nM [527232]
2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol Drug Info IC50 = 3 nM [527232]
4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol Drug Info IC50 = 24 nM [527966]
2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol Drug Info IC50 = 15 nM [526532]
4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol Drug Info IC50 = 9 nM [527966]
2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol Drug Info IC50 = 521 nM [527232]
7-(3-Hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 566 nM [527584]
4-Naphthalen-2-yl-phenol Drug Info IC50 = 245 nM [527584]
3-hydroxy-4-methyl-6H-benzo[c]chromen-6-one Drug Info IC50 = 1450 nM [527966]
3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one Drug Info IC50 = 90 nM [527966]
4,10-dimethyl-6H-benzo[c]chromene-3,8-diol Drug Info IC50 = 74 nM [527966]
Estrogen platinum(II) hybrid derivative Drug Info IC50 = 2800 nM [527267]
2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 59 nM [527232]
2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol Drug Info IC50 = 5.6 nM [527198]
4,7-dimethyl-6H-benzo[c]chromene-3,8-diol Drug Info IC50 = 88 nM [527966]
4',5,7-trihydroxy-6,8-dimethylisoflavone Drug Info IC50 = 880 nM [526493]
Geldanamycin-estradiol hybrid Drug Info IC50 = 80 nM [525501]
NARINGENIN Drug Info IC50 = 13473 nM [528557]
8-methylnaringenin Drug Info IC50 = 863 nM [528557]
8-n-nonylnaringenin Drug Info IC50 = 113 nM [528557]
8-(2-methylpropyl)naringenin Drug Info IC50 = 37 nM [528557]
4-(2-phenyl-1H-indol-3-yl)phenol Drug Info IC50 = 1.12 nM [527797]
7-Phenyl-naphthalen-2-ol Drug Info IC50 = 527 nM [527584]
6-Phenyl-naphthalen-2-ol Drug Info IC50 = 374 nM [527584]
6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 5 nM [527584]
SOPHORAFLAVANONE B Drug Info IC50 = 68 nM [528557]
8-benzylnaringenin Drug Info IC50 = 244 nM [528557]
4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol Drug Info IC50 = 52 nM [527681]
6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 2.8 nM [527584]
4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol Drug Info IC50 = 70 nM [526589]
3-hydroxy-4,10-dimethyl-6H-benzo[c]chromen-6-one Drug Info IC50 = 326 nM [527966]
2-(4-Hydroxy-phenyl)-quinolin-6-ol Drug Info IC50 = 171 nM [527681]
4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol Drug Info IC50 = 25 nM [527232]
4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol Drug Info IC50 = 75 nM [527681]
WAY-169916 Drug Info IC50 = 106 nM [527327]
4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol Drug Info IC50 = 137 nM [527797]
5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol Drug Info IC50 = 88 nM [527681]
6-(4-Hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 16 nM [527681]
6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 2 nM [527584]
6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 27 nM [527584]
6-(4-Hydroxy-phenyl)-naphthalen-1-ol Drug Info IC50 = 5.8 nM [527584]
2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol Drug Info IC50 = 1530 nM [527232]
2-(4-Hydroxy-phenyl)-benzofuran-5-ol Drug Info IC50 = 6 nM [527232]
6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 1.4 nM [527584]
6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 8.4 nM [527584]
6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol Drug Info IC50 = 199 nM [527584]
6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol Drug Info IC50 = 114 nM [527584]
3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol Drug Info IC50 = 46 nM [527232]
8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 1.6 nM [527584]
2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol Drug Info IC50 = 10 nM [527198]
3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol Drug Info IC50 = 254 nM [527232]
2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 66 nM [527232]
4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol Drug Info IC50 = 718 nM [527232]
7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 13 nM [527232]
2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol Drug Info IC50 = 1.42 nM [527232]
6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol Drug Info IC50 = 748 nM [527584]
5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol Drug Info IC50 = 157 nM [527232]
2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol Drug Info IC50 = 59 nM [527232]
2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol Drug Info IC50 = 3.5 nM [527232]
2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol Drug Info IC50 = 3660 nM [527232]
4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol Drug Info IC50 = 3 nM [527232]
2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol Drug Info IC50 = 703 nM [527232]
2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol Drug Info IC50 = 39 nM [527232]
7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 15 nM [527232]
2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol Drug Info IC50 = 533 nM [527232]
2-phenyl-1,2'-spirobi[1H-indene]-5'-ol Drug Info IC50 = 1070 nM [526532]
4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol Drug Info IC50 = 15 nM [526589]
3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one Drug Info IC50 = 46 nM [527966]
7-Bromo-2-(4-hydroxy-phenyl)-benzooxazol-5-ol Drug Info IC50 = 2 nM [527232]
THIOGENISTEIN Drug Info IC50 = 1340 nM [528131]
5,7-dihydroxy-3-phenyl-3H-quinazolin-4-one Drug Info IC50 = 18472 nM [528131]
3,4,6-Trihydroxy-2-(4-hydroxy-phenyl)-inden-1-one Drug Info IC50 = 1380 nM [527546]
7-hydroxy-3-(4-hydroxyphenyl)-3H-quinazolin-4-one Drug Info IC50 = 8609 nM [528131]
BITHIONOL Drug Info IC50 = 8147.15 nM [531262]
ZK-164015 Drug Info IC50 = 1.4 nM [527179]
1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol Drug Info Ki = 1.3 nM [527738]
4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol Drug Info IC50 = 200 nM [526589]
3'-Methoxy-4'Hydroxyclomiphene Drug Info IC50 = 780 nM [533383]
3,6-Dihydroxy-2-(4-hydroxy-phenyl)-inden-1-one Drug Info IC50 = 2625 nM [527546]
8-n-undecylnaringenin Drug Info IC50 = 421 nM [528557]
2-(4-Hydroxy-phenyl)-1-p-tolyl-3H-inden-5-ol Drug Info Ki = 1.3 nM [527738]
BROUSSONIN A Drug Info IC50 = 1800 nM [530935]
ARZOXIFENE Drug Info IC50 = 66.3 nM [528827]
1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 7 nM [527584]
[1,1':2',1'']Terphenyl-4'-carbaldehyde oxime Drug Info Ki = 0.27 nM [526711]
ANDROSTENEDIOL Drug Info IC50 = 9.9 nM [529061]
NAFOXIDINE Drug Info IC50 = 40.9 nM [534677]
COUMESTROL Drug Info IC50 = 18.6 nM [527550]
3-(4-Hydroxy-phenyl)-4H-chromen-7-ol Drug Info IC50 = 680 nM [527550]
7-(4-Hydroxy-phenyl)-naphthalen-2-ol Drug Info IC50 = 44 nM [527584]
2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol Drug Info IC50 = 29 nM [526532]
Doxorubicin-Formaldehyde Conjugate Drug Info IC50 = 300 nM [526966]
GNF-PF-3037 Drug Info IC50 = 2611.21 nM [531262]
MORIN Drug Info IC50 = 2927.18 nM [531262]
4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol Drug Info IC50 = 10 nM [526589]
References
Ref 528152Bioorg Med Chem Lett. 2006 Jul 1;16(13):3489-94. Epub 2006 May 2.The discovery of tetrahydrofluorenones as a new class of estrogen receptor beta-subtype selective ligands.
Ref 527797Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. Epub 2005 Oct 10.Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.
Ref 534119J Med Chem. 1996 Apr 26;39(9):1778-89.Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.
Ref 529314J Med Chem. 2008 Mar 13;51(5):1344-51. Epub 2008 Feb 13.Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor beta.
Ref 527797Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. Epub 2005 Oct 10.Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.
Ref 527797Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. Epub 2005 Oct 10.Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 525493Bioorg Med Chem Lett. 1999 Apr 19;9(8):1137-40.Synthesis and biological activity of trans-2,3-dihydroraloxifene.
Ref 526057J Med Chem. 2001 May 24;44(11):1654-7.Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens.
Ref 530935Bioorg Med Chem Lett. 2010 Jun 15;20(12):3764-7. Epub 2010 Apr 19.New estrogenic compounds isolated from Broussonetia kazinoki.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 529739Bioorg Med Chem. 2008 Nov 1;16(21):9554-73. Epub 2008 Sep 16.Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 526493J Nat Prod. 2002 Dec;65(12):1749-53.Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 526532Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).
Ref 526589J Med Chem. 2003 Apr 10;46(8):1484-91.Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527198Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.7-Substituted 2-phenyl-benzofurans as ER beta selective ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527198Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.7-Substituted 2-phenyl-benzofurans as ER beta selective ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 526532Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527267Bioorg Med Chem Lett. 2004 Dec 6;14(23):5919-24.Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers-molecular modeling studies.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527198Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.7-Substituted 2-phenyl-benzofurans as ER beta selective ligands.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 526493J Nat Prod. 2002 Dec;65(12):1749-53.Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis.
Ref 525501Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.Synthesis and evaluation of geldanamycin-estradiol hybrids.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 527797Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. Epub 2005 Oct 10.Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 526589J Med Chem. 2003 Apr 10;46(8):1484-91.Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527327J Med Chem. 2004 Dec 16;47(26):6435-8.Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis.
Ref 527797Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. Epub 2005 Oct 10.Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527681Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5.ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527198Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9.7-Substituted 2-phenyl-benzofurans as ER beta selective ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 526532Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).
Ref 526589J Med Chem. 2003 Apr 10;46(8):1484-91.Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
Ref 527966Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. Epub 2006 Jan 18.6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists.
Ref 527232J Med Chem. 2004 Oct 7;47(21):5021-40.Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Ref 528131J Med Chem. 2006 Apr 20;49(8):2440-55.Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.
Ref 528131J Med Chem. 2006 Apr 20;49(8):2440-55.Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.
Ref 527546Bioorg Med Chem Lett. 2005 Jun 15;15(12):3137-42.Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones.
Ref 528131J Med Chem. 2006 Apr 20;49(8):2440-55.Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.
Ref 531262Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).
Ref 527179Bioorg Med Chem Lett. 2004 Sep 20;14(18):4659-63.Synthesis and biological evaluation of stilbene-based pure estrogen antagonists.
Ref 527738J Med Chem. 2005 Sep 22;48(19):5989-6003.Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands.
Ref 526589J Med Chem. 2003 Apr 10;46(8):1484-91.Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.
Ref 533383J Med Chem. 1989 Jan;32(1):192-7.Phenolic metabolites of clomiphene: [(E,Z)-2-[4-(1,2-diphenyl-2-chlorovinyl)phenoxy]ethyl]diethylamine. Preparation, electrophilicity, and effects in MCF 7 breast cancer cells.
Ref 527546Bioorg Med Chem Lett. 2005 Jun 15;15(12):3137-42.Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 527738J Med Chem. 2005 Sep 22;48(19):5989-6003.Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands.
Ref 530935Bioorg Med Chem Lett. 2010 Jun 15;20(12):3764-7. Epub 2010 Apr 19.New estrogenic compounds isolated from Broussonetia kazinoki.
Ref 528827J Med Chem. 2007 May 31;50(11):2682-92. Epub 2007 May 10.Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 526711J Med Chem. 2003 Sep 11;46(19):4032-42.Novel estrogen receptor ligands based on an anthranylaldoxime structure: role of the phenol-type pseudocycle in the binding process.
Ref 529061Bioorg Med Chem Lett. 2007 Nov 15;17(22):6295-8. Epub 2007 Sep 7.Androstene-3,5-dienes as ER-beta selective SERMs.
Ref 534677J Med Chem. 1998 Jul 30;41(16):2928-31.Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
Ref 527550J Med Chem. 2005 May 19;48(10):3463-6.Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases.
Ref 527550J Med Chem. 2005 May 19;48(10):3463-6.Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases.
Ref 527584J Med Chem. 2005 Jun 16;48(12):3953-79.ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Ref 526532Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83.2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).
Ref 526966J Med Chem. 2004 Feb 26;47(5):1193-206.Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
Ref 531262Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).
Ref 531262Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).
Ref 526589J Med Chem. 2003 Apr 10;46(8):1484-91.Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.